Role of the T2Dx magnetic resonance assay in patients with suspected bloodstream infection: a single-centre real-world experience

BMC Infectious Diseases

Maria Carla Liberto¹  Giovanni Matera¹  Angela Quirino¹  Nadia Marascio¹  Cinzia Peronace¹  Alessandro Russo²  Vincenzo Scaglione²  Rosaria Lionello²  Francesca Serapide²  Carlo Torti²  Maria Mazzitelli²  Enrico Maria Trecarichi²  Eugenio Garofalo³  Federico Longhini³  Andrea Bruni³  Francesca Divenuto⁴  Grazia Pavia⁴  Chiara Costa⁵  Aida Giancotti⁵ 

[1] Unit of Clinical Microbiology, Department of Health Sciences, “Magna Graecia” University of Catanzaro-“Mater Domini” Teaching Hospital, Catanzaro, Italy;Unit of Infectious and Tropical Diseases, Department of Medical and Surgical Sciences, “Magna Graecia” University of Catanzaro-“Mater Domini” Teaching Hospital, Catanzaro, Italy;Unit of Intensive Care, Department of Medical and Surgical Sciences, “Magna Graecia” University of Catanzaro-“Mater Domini” Teaching Hospital, Catanzaro, Italy;“Magna Graecia” University of Catanzaro, Catanzaro, Italy;“Mater Domini” Teaching Hospital, Catanzaro, Italy;

关键词: Blood stream infections;    T2Dx;    ESKAPE;    Antimicrobial therapy;   

DOI  :  10.1186/s12879-022-07096-w

来源: Springer

【 摘 要 】

BackgroundT2Dx was approved by the US Food and Drug Administration for the rapid detection of a modified panel of ESKAPE bacterial species or Candida spp. causing bloodstream infection (BSI).Patients and methodsWe performed a retrospective, observational study from January 1, 2018 to December 31, 2019 of all hospitalised patients with suspected BSI who underwent assessment using T2Dx in addition to standard blood culture (BC). T2-positive patients (cases) were compared to a matched group of patients with BSI documented only by BC (1:2 ratio) to investigate the possible impact of T2Dx on the appropriateness of empirical antimicrobial therapy and 21-day mortality.ResultsIn total, 78 T2Dx-analysed samples (49 patients) were analysed. The T2Dx assay result was positive for18 patients and negative for 31 patients. The concordance rates of the T2Bacteria Panel and T2Candida Panel results with those of standard BC were 74.4% and 91.4%, respectively. In the matched analysis, inappropriate empiric antimicrobial therapy administration was significantly less frequent in cases than in comparators (5.5% vs. 38.8%). The 21-day mortality rate was twofold lower in cases than in comparators (22.2% vs. 44.4%), although the difference was not significant. No other analysed variables were significantly different between the two groups.ConclusionsThis study illustrated that T2Dx might be associated with an increase in the appropriateness of empiric antimicrobial therapy in patients with BSI. Further studies are needed to evaluate whether the T2Dx assay can improve patient outcomes.

【 授权许可】

CC BY